Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Healthcare & Life Sciences Fund CLASS C SHARES (ETCHX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.


1 month-2.76% 3 years+11.62%
3 months+7.14% 5 years--
1 year+13.14% Since inception+20.19%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return--+17.39%
Expense ratio2.35%1.33%
Risk 5 year sharpe ratio--1.14
Net assets$362.5M$3.1B
Average market cap$2.0B$31.6B
Average P/E--24.1
Portfolio turnover28%28%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 4 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00


U.S. stock78.29%
International stock10.44%
Fixed income1.60%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
SUPN Supernus Pharmaceuticals Inc3.35%
BLUE bluebird bio Inc3.20%
BPMC Blueprint Medicines Corp3.07%
LOXO Loxo Oncology Inc2.91%
KITE Kite Pharma Inc2.91%
CELG Celgene2.71%
VCYT Veracyte Inc2.47%
XNCR Xencor Inc2.38%
ONCE Spark Therapeutics Inc2.31%
DBVT DBV Technologies SA2.27%